Depemokimab-ulaa (Exdensur) | AETNA Coverage Update

Summary: Aetna modified CPB 1098 covering depemokimab-ulaa (Exdensur), effective May 8, 2026. Here's what billing teams need to know before submitting claims.

Aetna, a CVS Health company, updated its coverage policy for depemokimab-ulaa (Exdensur) under Clinical Policy Bulletin 1098 (CPB 1098 Aetna). Depemokimab is a long-acting anti-IL-5 biologic — the same class as mepolizumab and benralizumab — approved for severe eosinophilic asthma. This modification signals that Aetna has revised the criteria under which it considers depemokimab-ulaa billing medically justified. If your practice treats patients with severe asthma or eosinophilic conditions and bills Aetna plans, this coverage policy change affects you directly. The policy does not list specific CPT or HCPCS codes in the available data — more on that below.

Quick-Reference Table

Aetna Depemokimab-ulaa Coverage Criteria and Medical Necessity Requirements 2026

The Aetna depemokimab-ulaa coverage policy under CPB 1098 governs whether Exdensur qualifies for reimbursement under Aetna commercial and managed care plans. Because the FDA approved depemokimab-ulaa relatively recently, Aetna's criteria for this biologic are still being refined — which is exactly why a modification at this stage carries real financial risk for practices that aren't paying attention.

Biologics in the anti-IL-5 class — mepolizumab (Nucala), benralizumab (Fasenra), reslizumab (Cinqair) — all went through similar policy evolution at Aetna. Each payer established medical necessity thresholds tied to eosinophil counts, prior therapy failures, and asthma severity. Expect CPB 1098 to follow that same structure. If your documentation doesn't address those criteria explicitly, your claim is going to denial before anyone reads the notes.

Standard medical necessity requirements for this class of drugs at Aetna have historically included:

These are the criteria Aetna has applied to comparable anti-IL-5 agents. They are the most likely template for CPB 1098. That said — the specific thresholds and step therapy requirements for depemokimab-ulaa may differ from prior biologics in the class. Pull the full text of CPB 1098 directly from Aetna's provider portal and compare it line by line against what your documentation currently captures.

Prior authorization is required for specialty biologics like Exdensur under virtually all Aetna plans. Do not assume any path to reimbursement without prior auth approval in hand. Submit your prior authorization request with full supporting documentation: eosinophil lab values, prescription history, pulmonary function test results, and physician attestation of medical necessity.

If you're unsure how CPB 1098 applies to your specific plan mix — commercial, Medicare Advantage, or Medicaid managed care — talk to your compliance officer before May 8, 2026.

Aetna Depemokimab-ulaa Exclusions and Non-Covered Indications

Aetna's coverage policy for biologics in this class consistently excludes certain uses from reimbursement. Based on the policy structure used for comparable anti-IL-5 agents, expect CPB 1098 to exclude:

Off-label indications without sufficient clinical evidence. Depemokimab-ulaa's FDA approval is specific. Billing for indications outside that approval — without strong peer-reviewed evidence and specific payer approval — will result in claim denial.

Use as initial therapy without step therapy. Aetna requires documented failure of standard-of-care inhaled therapies before it considers a biologic medically necessary. A claim that skips that step won't survive review.

Duplicate biologic therapy. Aetna does not cover concurrent use of two anti-IL-5 or anti-IL-4/13 biologics. If your patient is already on dupilumab or another approved biologic, the prior authorization for depemokimab-ulaa will likely be denied without a documented rationale for the switch.

These are pattern exclusions. Verify against the actual CPB 1098 text. The precise language matters when you're writing an appeal.

Coverage Indications at a Glance

The policy data available does not include indication-level detail for CPB 1098. The table below reflects the expected coverage structure based on FDA approval and Aetna's historical approach to anti-IL-5 biologics. Treat this as a working framework — not a substitute for reading the full CPB 1098 text.

Aetna Depemokimab-ulaa Billing Guidelines and Action Items 2026

Here's what your billing and prior authorization teams need to do right now.

CPT, HCPCS, and ICD-10 Codes for Depemokimab-ulaa Under CPB 1098

The available policy data for CPB 1098 does not include specific CPT, HCPCS, or ICD-10 codes. This is not unusual for a recently modified bulletin — code assignments for new biologics sometimes lag the policy text.

Here's how to handle this gap:

For HCPCS codes: Depemokimab-ulaa (Exdensur) received FDA approval in 2024. CMS typically assigns a new HCPCS J-code to new biologics within one to two years of approval. Check the CMS HCPCS quarterly update and Aetna's drug-specific billing guidelines for the current assigned code. If a permanent J-code is not yet assigned, the applicable code is likely J3490 (unclassified drugs) or J3590 (unclassified biologics) — but confirm this with Aetna before billing to avoid automatic claim denial on unclassified code submissions without accompanying documentation.

For ICD-10 diagnosis codes: The primary diagnosis supporting medical necessity for severe eosinophilic asthma billing will come from the J45.x asthma code range. Document the specific asthma severity and eosinophilic subtype clearly in the medical record. If billing for an off-label indication, the ICD-10 code selection becomes even more critical — it has to align precisely with whatever indication Aetna's CPB 1098 recognizes.

Do not bill a code you cannot source directly from the published CPB 1098 text or Aetna's drug billing guidelines. Invented or assumed codes are a fast path to claim denial and, in audits, a compliance problem.